NatResearchCancer

@NatResCancer

The Nature Research editors handling cancer primary research, methods, protocols and reviews. The latest articles, covering all aspects of cancer research

London, New York, Berlin, Shanghai
Vrijeme pridruživanja: listopad 2017.

Tweetovi

Blokirali ste korisnika/cu @NatResCancer

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @NatResCancer

  1. Prikvačeni tweet
    13. ožu 2018.

    What's going on in cancer at Nature Research? Check out , and sign up for our weekly e-alerts to receive highlights direct to your inbox!

    Poništi
  2. proslijedio/la je Tweet

    A new article from Rubén Pio Lab shows intermittent fasting synergizes with PD-1 blockade to inhibit lung cancer progression and metastasis. Please read the full article here article:

    Poništi
  3. proslijedio/la je Tweet
    4. velj

    A year ago today I announced that we were creating to lend a new voice to the community and help in the fight against cancer

    Prikaži ovu nit
    Poništi
  4. proslijedio/la je Tweet

    Interested in an editorial career with in the field of ? We are now hiring a new associate or senior editor, to be based in London or New York. Learn more & apply before Feb 17:

    Poništi
  5. proslijedio/la je Tweet
    4. velj
    Poništi
  6. proslijedio/la je Tweet

    A Review in Nature Reviews Immunology summarizes current knowledge of the roles of B cells and antibodies in the tumour microenvironment.

    Poništi
  7. proslijedio/la je Tweet
    31. sij

    When applied retrospectively to a a phase III trial, a system for ctDNA with filtering of alterations from matched white blood cells predicted recurrence when applied within 9 weeks after preoperative treatment and surgery in patients with gastric cancer:

    Poništi
  8. proslijedio/la je Tweet
    30. sij
    Prikaži ovu nit
    Poništi
  9. proslijedio/la je Tweet

    In , Brid Ryan demonstrate higher frequency of homologous recombination deficiency in tumours from African Americans than European Americans - call for diverse pop'ns in cancer genomics studies

    Poništi
  10. proslijedio/la je Tweet
    31. sij

    500 followers, lovely! I'm always trying to reach more people to help spread the word about cancer genetics and epigenetics. I'm based , working closely with and all the gang

    Prikaži ovu nit
    Poništi
  11. proslijedio/la je Tweet
    30. sij

    Transformable peptide nanoparticles, which self-assemble into micelles under aqueous conditions but on binding to HER2 on cancer cells transform into nanofibrils that disrupt HER2 dimerization, arrest HER2 signalling and cause cancer cell death in vivo:

    Poništi
  12. proslijedio/la je Tweet
    31. sij

    wonderful deep dive on intra-tumour heterogeneity in liver cancer- fascinating interplay of spatio-temporal immune/cancer cell interactions

    Prikaži ovu nit
    Poništi
  13. proslijedio/la je Tweet
    29. sij

    Online at : “Tobacco smoking and somatic mutations in human bronchial epithelium” by Peter Campbell and colleagues and News and Views:

    Poništi
  14. proslijedio/la je Tweet

    In our FEBRUARY issue out NOW we have all of this: the PI3K–AKT signalling network in ; the ageing microenvironment in tumour progression; fluids & mechanics of metastatic dissemination; dietary patterns & risk

    Poništi
  15. proslijedio/la je Tweet
    30. sij

    ATACseq and scRNAseq in chronic lymphocytic leukaemia shows temporal response to ibrutinib. Fascinating paper!

    Poništi
  16. proslijedio/la je Tweet

    for 1 month: Towards a comprehensive catalogue of validated and target-linked human enhancers by , Jacob Tome &

    Prikaži ovu nit
    Poništi
  17. proslijedio/la je Tweet

    A new paper in by Dr. Kochenderfer and colleagues at supports the idea that we can design and improve CAR T-cell therapies to have fewer negative effects for patients.

    Prikaži ovu nit
    Poništi
  18. proslijedio/la je Tweet

    Tests of thousands of drugs not originally developed for oncology across 578 human cancer cell lines reveals growth-inhibitory effects and provides a way to identify drugs with the potential to be repurposed for cancer, according to a paper.

    Poništi
  19. proslijedio/la je Tweet
    27. sij

    Last week, the FDA approved the EZH2 inhibitor tazemetostat as the first treatment option specifically for advanced-stage epithelioid sarcoma, which accounts of <1% of soft-tissue sarcomas, based on an ORR of 15%, with 67% of responses lasting >/=6 months:

    Poništi
  20. proslijedio/la je Tweet

    Our Consensus Statement provides a framework for advancing our understanding of cancer-associated fibroblasts authored by 29 leaders in the field! Why not have a read here....

    Poništi
  21. proslijedio/la je Tweet
    25. sij

    is a subscription journal but we can provide you with a shareable link to read the inspiring story of the ROS1ders (You will not be able to download but can read and share)

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·